Virginia Borges, MD

Panelists spotlight key trials and drugs to watch in ongoing research in triple-negative breast cancer.

Panelists break down other key triple-negative breast cancer data presented at the 2025 ESMO Congress.

Panelists discuss findings from the TROPION-Breast02 trial evaluating first-line datopotamab deruxtecan in immunotherapy-ineligible triple-negative breast cancer.

Panelists discuss sequencing considerations as more TROP-2–directed antibody-drug conjugates are evaluated in triple-negative breast cancer.

Panelists discuss safety considerations for sacituzumab govitecan–based therapy in frontline triple-negative breast cancer.

Panelists highlight findings from the ASCENT-03 trial evaluating sacituzumab govitecan in triple-negative breast cancer ineligible for immunotherapy.

Panelists break down data from the ASCENT-04 trial evaluating sacituzumab govitecan plus pembrolizumab in triple-negative breast cancer.

Panelists discuss the current state of the frontline treatment paradigm for advanced triple-negative breast cancer

The panel closes their discussion by summarizing the most exciting recent advances in HER2+ breast cancer, the future of treatment, and unmet needs that must be addressed.

The panel highlights emerging data from SABCS 2022 on investigational agents being explored for HER2+ mBC treatment.

The panel discusses the management of patients with HER2+ mBC with asymptomatic brain mets and shares their thoughts on the use of surveillance brain MRI in this setting.

Maryam Lustberg, MD, MPH introduces the standard of care regimens for the second-line treatment of HER2+ metastatic breast cancer, followed by a discussion of recent data on the ADC trastuzumab deruxtecan (T-DXd).

Dr Debu Tripathy explains the treatment options for patients with HER2+ metastatic breast cancer in the third-line and later-line settings, including combination tucatinib/trastuzumab/capecitabine.

The panel highlights recent data updates in adjuvant treatment of HER2+ early breast cancer, including longer-term follow-up data from the APT and ATEMPT trials.

A focused discussion on available options for the first-line treatment of HER2+ metastatic breast cancer (mBC), with reference to data from the CLEOPATRA trial.

Joyce O’Shaughnessy, MD, starts a conversation on which patients with HER2+ early breast cancer are the best candidates for extended adjuvant neratinib therapy.

A review of recently reported data on the use of adjuvant pertuzumab/trastuzumab for the treatment of HER2+ early breast cancer, including data from the APHINITY and PHranceSCa trials.

The panel explains their clinical experiences with using the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) to treat HER2+ early breast cancer.

A look at how patient response to neoadjuvant treatment for HER2+ early breast cancer informs adjuvant treatment selection.

The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.

Debu Tripathy, MD, details when he utilizes a treatment de-escalation approach in his patients with HER2+ early breast cancer.

A review of the standard of care regimens for the preoperative or neoadjuvant treatment of HER2+ early breast cancer.

Virginia Borges, MD, explains how common HER2+ early breast cancer is and the goals of treatment for patients.